Pelthos Therapeutics, a biopharmaceutical company specializing in treatments for cutaneous infectious diseases, will announce its first quarter 2026 financial results on May 14, 2026. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss the results and answer questions. Pelthos is known for products like ZELSUVMI™ gel for Molluscum contagiosum, Xepi® cream for impetigo, and Xeglyze® for head lice. Investors and interested parties can join the webcast or call using provided details.
C-Lingo, a Hong Kong-based company, introduced a new AI-driven platform on May 23, 2026, to transform Chinese language education in Vietnam. The platform uses a unique "Connected Learning" model combining AI personalization and gamification to enhanc...
The Pentagon has informed Japan that delivery of 400 Tomahawk cruise missiles, ordered in 2024 under a $2.35 billion deal, will face delays of up to two years. This is due to the US military prioritizing replenishment of missile stockpiles heavily us...
The Fidelity Dividend ETF for Rising Rates (FDRR), targeting dividend payers linked to Treasury yields, has underperformed key benchmarks like SPY despite its focus on rising interest rates. While FDRR offers value traits and dividend growth exceedin...
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
Rosen Law Firm is investigating potential securities claims against Futu Holdings following allegations that the company issued misleading business information. The probe comes after China announced a crackdown on brokers, including Futu, for operati...
